Michelle M. Le Beau, PhD, FAACR
AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research

Michelle M. Le Beau, PhD, FAACR

Arthur and Marian Edelstein Professor of Medicine
University of Chicago Medicine Comprehensive Cancer Center
University of Chicago
Chicago, Illinois

For using cytogenetic and molecular genetic tools to identify critical recurring abnormalities in human leukemia, including inversions, translocations, and deletions of chromosomes 5 and 7 in leukemia following cancer treatment and for serving as a tireless champion of cancer research on the international stage.

The Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research was established in 2007 to recognize a champion of cancer research whose leadership and extraordinary achievements in cancer research have had a major impact on the field. Such achievements may include scientific contributions to the acceleration of progress against cancer, significant accomplishments associated with national or international awareness of the importance of cancer research, or other ways of demonstrating a sustained extraordinary commitment to cancer research. 

Le Beau is an international authority on the molecular analysis of recurring chromosomal abnormalities in human leukemias and lymphomas, the correlation of specific abnormalities with morphological and clinical features, and the development of risk-adapted therapy. Through her work, she has been instrumental in deepening the understanding of the onset and progression of numerous hematological malignancies, including implicating deletions on chromosomes 5 and 7 as oncogenic drivers of therapy-related myeloid leukemias. Her current work focuses on the analysis of the genes on chromosome 5 that are involved in therapy-related AML; the development and characterization of mouse models harboring AML driver mutations; the identification of secondary mutations and genetic pathways essential to leukemogenesis; and the application of mouse models for preclinical testing of potential therapeutics. To learn more, please visit the press release.

View Past Recipients